# EDGAR Filing Document

**Accession Number:** 0001812360
**File Stem:** 0001213900-23-005774
**Filing Date:** 2023-1
**Character Count:** 12557
**Document Hash:** 077ce5963fef514637acea8894229726
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-23-005774.hdr.sgml**: 20230315

**ACCESSION NUMBER**: 0001213900-23-005774

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20230127

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FOXO TECHNOLOGIES INC.
- **CENTRAL INDEX KEY:** 0001812360
- **STANDARD INDUSTRIAL CLASSIFICATION:** LIFE INSURANCE [6311]
- **IRS NUMBER:** 851050265
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 729 WASHINGTON AVE. N
- **STREET 2:** SUITE 600
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55401
- **BUSINESS PHONE:** (612) 562-9447

**MAIL ADDRESS:**
- **STREET 1:** 729 WASHINGTON AVE. N
- **STREET 2:** SUITE 600
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Delwinds Insurance Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200518

---

| |
|:---|
| ![](image_001.jpg) |
| Mitchell Silberberg & Knupp llp<br> A Law Partnership Including Professional Corporations |

---

***<u>VIA EDGAR</u>***

January 27, 2023

U.S. Securities & Exchange Commission<br> Division of Corporation Finance

Office of Finance

100 F Street, NE

Washington, D.C. 20549

---

| | |
|:---|:---|
| Attn: | David Gessert |
|  | David Lin |
|  | Division of Corporation Finance |
|  | Office of Finance |

---

---

| | |
|:---|:---|
| Re: | **FOXO Technologies Inc.** |
|  | **Registration Statement on Form S-1** |
|  | **Filed December 23, 2022** |
|  | **File No. 333-268980** |

---

Ladies and Gentlemen:

On behalf of our client, FOXO Technologies Inc., a Delaware corporation (the "**Company**" or "**FOXO**"), and pursuant to the applicable provisions of the Securities Act of 1933, as amended, and the rules promulgated thereunder, we are submitting (i) this letter to the Securities and Exchange Commission (the "**Commission**") via EDGAR in response to the comment letter to Mr. Robert Potashnick, the Company's Chief Financial Officer, from the staff of the Commission (the "**Staff**"), dated January 19, 2023 (the "**FOXO Comment Letter**"), pertaining to the Company's above-referenced Registration Statement on Form S-1 (the **Registration Statement**") and (ii) a complete copy of Amendment No. 1 ("**Amendment No. 1**") to the Registration Statement.

Amendment No. 1 reflects certain revisions to the Registration Statement in response to the FOXO Comment Letter and other updated information.

The numbered paragraphs in bold below set forth the Staff's comments together with the Company's responses. Disclosure changes made in response to the Staff's comments have been made in Amendment No. 1, which is being filed with the Commission contemporaneously with the submission of this letter. Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the Amendment No. 1.

437 Madison Ave., 25th Floor, New York, New York 10022-7001<br> Phone: (212) 509-3900 Fax: (212) 509-7239 Website: www.msk.com

![](image_001.jpg)

<u>Registration Statement on Form S-1 General</u>

1. Revise your prospectus to disclose the price that each selling
securityholder paid for the securities being registered for resale. Highlight any differences in the current trading price, the prices
that the Sponsor, private placement investors and other selling securityholders acquired their shares and warrants, and the price that
the public securityholders acquired their shares and warrants. Disclose that while the Sponsor, private placement investors and other
selling securityholders may experience a positive rate of return based on the current trading price, the public securityholders may not
experience a similar rate of return on the securities they purchased due to differences in the purchase prices and the current trading
price. Please also disclose the potential profit the selling securityholders will earn based on the current trading price. Lastly, please
include appropriate risk factor disclosure.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on the prospectus cover page, and pages ii, 6 and 111 of Amendment No. 1.

2. Please revise to update your disclosures throughout the filing to address areas that appear to need updating
in light of developments since the consummation of your Business Combination. Non-exclusive examples of areas where disclosure should
be updated are as follows:

● Revise throughout to disclose your planned sale of FOXO Life to Security National Life Insurance Company, as disclosed in your Form 8-K filed January 12, 2023, and discuss its impact upon your planned business activities;

**<u>Response</u>:** In response to the Staff's comment, the Company has updated the disclosure on pages 4, 38 and 48 of Amendment No. 1.

● Revise the Prospectus Summary to disclose the reasons the ELOC and Forward Purchase Agreements with the Cantor Investor and Meteora, respectively, were terminated; and

**<u>Response</u>:** In response to the Staff's comment, the Company has updated the disclosure on pages 5, 38 and 39 of Amendment No. 1.

● Revise the Prospectus Summary to disclose the reasons why Jon Sabes and Steve Sabes were terminated as the company's Chief Executive Officer and Chairman and Chief Operating Officer, respectively. In this regard, we note that your registration statement filed in connection with your Business Combination included risk factor disclosure that your future success depends in large part on the continued participation in the business of Jon Sabes, FOXO's founder and Chief Executive Officer of the combined company. Please update your disclosure to address the risks related to Jon Sabes' departure.

**<u>Response</u>:** In response to the Staff's comment, the Company has updated the disclosure on pages 5, 10 and 39 of Amendment No. 1.

![](image_001.jpg)

<u>Cover Page</u>

3. For each of the Class A common shares and warrants being registered for resale, disclose the price that
the selling securityholders paid for such shares and warrants or the securities overlying such shares and warrants.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on the prospectus cover page, and pages ii, 9 and 111 of Amendment No. 1.

4. Disclose the exercise price(s) of the warrants compared to the market price of the underlying security.
If the warrants are out the money, please disclose the likelihood that warrant holders will not exercise their warrants. Provide similar
disclosure in the prospectus summary, risk factors, MD&A and use of proceeds section and disclose that cash proceeds associated with
the exercises of the warrants are dependent on the stock price. As applicable, describe the impact on your liquidity and update the discussion
on the ability of your company to fund your operations on a prospective basis with your current cash on hand.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on the prospectus cover page, and pages 6, 9, 33 and 49 of Amendment No. 1.

5. We note the significant number of redemptions of your Class A Common Stock in connection with your Business
Combination and that the shares being registered for resale will constitute a considerable percentage of your public float. To the extent
that all or most of the shares being registered for resale were purchased by the selling securityholders for prices considerably below
the current market price of your Class A Common Stock, please also highlight the significant negative impact sales of shares on this registration
statement could have on the public trading price of your Class A Common Stock.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on pages 9 and 49 of Amendment No. 1.

<u>Risk Factors, page 8</u>

6. Include an additional risk factor highlighting the negative pressure potential sales of shares pursuant
to this registration statement could have on the public trading price of your Class A Common Stock. To illustrate this risk, disclose
the purchase price of the securities being registered for resale and the percentage that these shares currently represent of the total
number of shares outstanding. Also disclose, if true, that even though the current trading price is significantly below the SPAC IPO price,
certain private investors may have an incentive to sell because they may still profit on sales because of the lower price that they purchased
their shares than the public investors.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on page 9 of Amendment No. 1.

![](image_001.jpg)

<u>Management's Discussion and Analysis of Financial Condition and Results of Operations, page 33</u>

7. We note that the projected revenues for 2022 were $2 million, as set forth in the unaudited prospective
financial information FOXO's management provided to Delwinds in connection with the evaluation of the Business Combination. We also
note that your actual revenues for the Nine Months Ended September 30, 2022 were approximately $93 thousand. It appears that you will
miss your 2022 revenue projection. Please update your disclosure in Liquidity and Capital Resources, and elsewhere, to provide updated
information about the company's financial position and further risks to the business operations and liquidity in light of these
circumstances.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on page 49 of Amendment No. 1.

<u>Overview, page 33</u>

8. In light of the significant number of redemptions and the unlikelihood that the company will receive significant
proceeds from exercises of the warrants because of the disparity between the exercise price of the warrants and the current trading price
of your Class A Common Stock, expand your discussion of capital resources to address any changes in the company's liquidity position
since the Business Combination. If the company is likely to have to seek additional capital, discuss the effect of this offering on the
company's ability to raise additional capital.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on pages 9, 13 and 49 of Amendment No. 1.

9. Please expand your discussion here to reflect the fact that this offering involves the potential sale of a substantial portion of
shares for resale and discuss how such sales could impact the market price of your Class A Common Stock.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on pages 9, 49, and 113 of Amendment No. 1.

10. We note that in connection with the termination of your Forward Purchase Agreement with Meteora you repurchased
the remaining shares subject to the agreement that Meteora had not already sold in the open market and were not part of the maturity consideration.
Please revise to disclose the number of shares you repurchased and the per share and aggregate consideration you paid. Additionally, discuss
the impact of the repurchases on the cash you have available for other purposes and to execute your business strategy. Provide cross references
to this discussion elsewhere in the prospectus where this agreement is referenced.

**<u>Response</u>:** In response to the Staff's comment, the Company has revised the disclosure on pages 5 and 39 of Amendment No. 1.

![](image_001.jpg)

<u>Executive Compensation, page 79</u>

11. We note that subsequent to the filing of Form S-1, the company's fiscal year ended. Accordingly,
your next amendment should include updated executive compensation information for your most recently completed fiscal year pursuant to
Item 402 of Regulation S-K. For guidance, refer to Question 117.05 of the Compliance and Disclosure Interpretations for Regulation S-K.

**<u>Response</u>:** In response to the Staff's comment and pursuant to Item 402 of Regulation S-K, the Company has updated the executive compensation information in Amendment No. 1.

\*\*\*

We thank the Staff for its review of the foregoing and Amendment No. 1. If you have further comments, please do not hesitate to contact me at bjb@msk.com or by telephone at (917) 546-7709.

---

| |
|:---|
| Sincerely, |
| */s/ Blake Baron* |
| Name: Blake Baron |

---

cc: Robert Potashnick, FOXO Technologies Inc.

Nimish Patel, Mitchell Silberberg & Knupp LLP